摘要
肝细胞癌(HCC)是起源于肝细胞的恶性肿瘤,中国80%以上HCC患者合并有乙型肝炎病毒感染。HCC通常是一种富血供肿瘤,经动脉化疗栓塞(TACE)治疗一方面阻断肿瘤血供,同时在肿瘤局部聚集高浓度的化疗药物,对肿瘤细胞发挥最大限度的杀伤作用,被公认为是不可切除HCC治疗的首要治疗方法。中国医师协会介入医师分会专家们经讨论针对《中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南》2018年版进行更新。
Hepatocellular carcinoma(HCC)is a malignancy originating from liver cells.Hepatitis B virus(HBV)is the major etiological factor contributed to the development of HCC in China.Pathologically,HCC is usually characterized of hypervascularity.The rationale of transarterial chemoembolization(TACE)is that the intraarterial infusion of cytotoxic agents followed by embolization of the tumor-feeding blood vessels causes a strong tumor killing effect.TACE is the most widely used primary treatment for unresectable HCC.In 2018,Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma were published by Chinese College of Interventionalists.After several clinical and scientific advances are achieved,a new version of practice guidelines is updated in 2021.
作者
中国医师协会介入医师分会临床诊疗指南专委会
滕皋军
赵明
朱海东
夏冬东
靳勇
刘嵘
Clinical Guidelines Committee of Chinese Interventionalists College;Teng Gaojun(不详;Department of Interventional Radiology and Vascular Surgery,Affiliated Zhongda Hospital,School of Medicine,Southeast University,Nanjing 210009,China)
出处
《中华内科杂志》
CAS
CSCD
北大核心
2021年第7期599-614,共16页
Chinese Journal of Internal Medicine
关键词
癌
肝细胞
栓塞
治疗性
实践指南
经动脉化疗栓塞
Carcinoma,hepatocellular
Embolization,therapeutic
Practice guideline
Transarterial chemoembolization
